In general, HSCT is a treatment option for many hematologic disorders like AML in first remission, ALL with poor prognosis, for chronic myeloid leukemia (CML) besides the TRK inhibitor imatinib (Gleevec®) or myeloproliferative disorders other than CML, MDS, chronic lymphocytic leukemia, HL in the R/R setting, myeloma, AL-amyloidosis, acquired severe aplastic anemia or constitutional severe aplastic anemia in FA [232]. This evidence concerns the gene NTRK1 and acute myeloid leukemia.